Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA2M7V)

Drug Name

LY3372689 Drug Info

Synonyms

LY3372689; U0SGP6ZX2V; LY-3372689; UNII-U0SGP6ZX2V; 2241514-56-5; Acetamide, N-(4-fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)-1-piperidinyl)methyl)-2-thiazolyl)-; CHEMBL5095251; SCHEMBL20421995; GTPL11953; GLXC-25705; EX-A6549; MS-26295; HY-144681; CS-0433932; N-(4-Fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)piperidin-1-yl)methyl)thiazol-2-yl)acetamide; N-[4-fluoro-5-[[(2S,4S)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1]

Cross-matching ID

PubChem CID: 135260636
TTD Drug ID: DMA2M7V

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Beta-N-acetylhexosaminidase (OGA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MK 8719	DMFLP21	Progressive supranuclear palsy	8A00.10	Phase 1	[2]
MK-8719	DMETIBD	Progressive supranuclear palsy	8A00.10	Phase 1	[3]
ASN51	DMZWOYL	Alzheimer disease	8A20	Phase 1	[4]
BIIB113	DM7U1AC	Alzheimer disease	8A20	Phase 1	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Beta-N-acetylhexosaminidase (OGA)	TT2I6UX	OGA_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05063539) Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies. J Med Chem. 2019 Nov 27;62(22):10062-10097.
4	Clinical pipeline report, company report or official report of Asceneuron
5	ClinicalTrials.gov (NCT05195008) A Phase 1 Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With an Open-Label Target Occupancy Study of BIIB113 in Healthy Participants. U.S.National Institutes of Health.